Kirsten E Smith1, Kelly E Dunn, Jeffrey M Rogers, Albert Garcia-Romeu, Justin C Strickland, David H Epstein. 1. Real-world Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, USA (KES, JMR, DHE); Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA (KED, AGR, JCS).
Abstract
INTRODUCTION: Since 2007, kratom use in the United States has increased, centered around nonmedical self-treatment of pain, psychiatric, and substance use disorder symptoms. Reports of kratom withdrawal have emerged amidst description of therapeutic effects, yet we know little about disordered use. Our objective was to assess Diagnostic and Statistical Manual-5 substance use disorder for kratom ("kratom use disorder," KUD) and examine kratom withdrawal symptoms among those who ever used regularly. We also sought to identify clinical characteristics of respondents who qualified for current, remitted, or never KUD. METHODS: Between April and May 2021, we re-recruited online respondents who reported lifetime kratom use on an unrelated survey into our cross-sectional kratom survey study, permitting a diverse sample of current and former kratom-using persons. RESULTS: A total of 129/289 (44.6%) evaluable surveys were obtained. Over half (52.7%) of respondents never met KUD diagnostic criteria; 17.8% were assessed remitted, and 29.5% met current (past-year) KUD threshold. For past-year KUD, severity was: 14.0% mild, 7.0% moderate, and 8.5% severe. Pain, psychiatric symptoms, and polydrug use were found across all groups. KUD symptoms reflected increased use, tolerance, withdrawal, unsuccessful quit attempts, and craving; 9.3% reported decreases in important social, occupational, or recreational activities because of use. Withdrawal symptoms were moderate and included gastrointestinal upset, restlessness, anxiety, irritability, fatigue/low energy, and craving. CONCLUSIONS: As assessed here, tolerance and withdrawal are primary KUD features rather than psychosocial impairments. As kratom is often used among persons with a myriad of health conditions, clinicians should be aware of and assess for kratom use and withdrawal.
INTRODUCTION: Since 2007, kratom use in the United States has increased, centered around nonmedical self-treatment of pain, psychiatric, and substance use disorder symptoms. Reports of kratom withdrawal have emerged amidst description of therapeutic effects, yet we know little about disordered use. Our objective was to assess Diagnostic and Statistical Manual-5 substance use disorder for kratom ("kratom use disorder," KUD) and examine kratom withdrawal symptoms among those who ever used regularly. We also sought to identify clinical characteristics of respondents who qualified for current, remitted, or never KUD. METHODS: Between April and May 2021, we re-recruited online respondents who reported lifetime kratom use on an unrelated survey into our cross-sectional kratom survey study, permitting a diverse sample of current and former kratom-using persons. RESULTS: A total of 129/289 (44.6%) evaluable surveys were obtained. Over half (52.7%) of respondents never met KUD diagnostic criteria; 17.8% were assessed remitted, and 29.5% met current (past-year) KUD threshold. For past-year KUD, severity was: 14.0% mild, 7.0% moderate, and 8.5% severe. Pain, psychiatric symptoms, and polydrug use were found across all groups. KUD symptoms reflected increased use, tolerance, withdrawal, unsuccessful quit attempts, and craving; 9.3% reported decreases in important social, occupational, or recreational activities because of use. Withdrawal symptoms were moderate and included gastrointestinal upset, restlessness, anxiety, irritability, fatigue/low energy, and craving. CONCLUSIONS: As assessed here, tolerance and withdrawal are primary KUD features rather than psychosocial impairments. As kratom is often used among persons with a myriad of health conditions, clinicians should be aware of and assess for kratom use and withdrawal.
Authors: Albert Garcia-Romeu; David J Cox; Kirsten E Smith; Kelly E Dunn; Roland R Griffiths Journal: Drug Alcohol Depend Date: 2020-02-03 Impact factor: 4.492
Authors: Marion A Coe; Janine L Pillitteri; Mark A Sembower; Karen K Gerlach; Jack E Henningfield Journal: Drug Alcohol Depend Date: 2019-06-29 Impact factor: 4.492
Authors: Erin C Berthold; Shyam H Kamble; Kanumuri S Raju; Tamara I King; Raluca Popa; Abhisheak Sharma; Francisco León; Bonnie A Avery; Lance R McMahon; Christopher R McCurdy Journal: J Pharm Biomed Anal Date: 2020-11-21 Impact factor: 3.935
Authors: Francisco León; Samuel Obeng; Marco Mottinelli; Yiming Chen; Tamara I King; Erin C Berthold; Shyam H Kamble; Luis F Restrepo; Avi Patel; Lea R Gamez-Jimenez; Carolina Lopera-Londoño; Takato Hiranita; Abhisheak Sharma; Aidan J Hampson; Clinton E Canal; Lance R McMahon; Christopher R McCurdy Journal: J Med Chem Date: 2021-09-01 Impact factor: 8.039
Authors: Nelson Jeng-Yeou Chear; Francisco León; Abhisheak Sharma; Siva Rama Raju Kanumuri; Grant Zwolinski; Khalil A Abboud; Darshan Singh; Luis F Restrepo; Avi Patel; Takato Hiranita; Surash Ramanathan; Aidan J Hampson; Lance R McMahon; Christopher R McCurdy Journal: J Nat Prod Date: 2021-02-26 Impact factor: 4.050
Authors: Shyam H Kamble; Erin C Berthold; Tamara I King; Siva Rama Raju Kanumuri; Raluca Popa; Julius R Herting; Francisco León; Abhisheak Sharma; Lance R McMahon; Bonnie A Avery; Christopher R McCurdy Journal: J Nat Prod Date: 2021-02-23 Impact factor: 4.050
Authors: Alessandro E Vento; Simone de Persis; Sergio De Filippis; Fabrizio Schifano; Flavia Napoletano; John M Corkery; Georgios D Kotzalidis Journal: Front Psychiatry Date: 2021-03-31 Impact factor: 4.157
Authors: Kirsten E Smith; Jeffrey M Rogers; Kelly E Dunn; Oliver Grundmann; Christopher R McCurdy; Destiny Schriefer; David H Epstein Journal: Front Pharmacol Date: 2022-03-01 Impact factor: 5.810